Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting

Kathryn L Hackman, Claudia Gagnon, Roisin K Briscoe, Simon Lam, Mahesan Anpalahan and Peter R Ebeling

Vitamin D deficiency is highly prevalent in Australia. Evidence of beneficial effects of vitamin D on bone health and muscle strength, and more recently on other organ systems, has emerged. Vitamin D replacement should increase serum 25-hydroxyvitamin D (25(OH)D) levels to over 50 nmol/L, and ideally to above 75 nmol/L.

Vitamin D deficiency in Australia is most commonly treated with preparations containing 1000 IU of cholecalciferol. However, in moderate to severe vitamin D deficiency, cholecalciferol 3000 to 5000 IU daily for up to 3 months is usually required, potentially reducing compliance with treatment. High-dose oral formulations are available in many countries, but are not approved for routine use in Australia. The Australian experience of high-dose vitamin D therapy is limited and few studies of high-dose vitamin D have assessed urinary calcium excretion.

This prospective, randomised, open-label trial aimed to compare the efficacy and safety of a 10-day course of high-dose oral cholecalciferol with a 3-month daily low-dose regimen.

METHODS

Inpatients at the Western and Sunshine Hospitals in Melbourne with serum levels of 25(OH)D \(\leq\) 50 nmol/L, between March 2007 and January 2008, were eligible. Patients receiving vitamin D supplements or with hypercalcaemia, Paget disease of bone, active malignancy, thyrotoxicosis, hypercalciuria, serum creatinine concentrations of > 150 \(\mu\)mol/L, or a history of nephrolithiasis were excluded. Ethical approval was obtained from the Melbourne Health Human Research Ethics Committee. The study was registered with the Australian Clinical Trials Registry (ACTRN 12607000338460).

Patients were randomly assigned to either a high-dose group or a low-dose group. Each patient in the high-dose group received an oral tablet of cholecalciferol 50 000 IU (Cal-D-Forte, API Consumer Brands) daily for 10 days (a total dose of cholecalciferol 500 000 IU). Each patient in the low-dose group received three tablets of cholecalciferol 1000 IU (OsteVit-D, Key Pharmaceuticals) daily for 30 days, followed by one tablet daily for 60 days (a total dose of 150 000 IU). All patients were prescribed calcium citrate 500 mg daily. Compliance with cholecalciferol treatment was assessed by direct questioning (> 80% of tablets taken).

The primary end points were the absolute change in serum 25(OH)D and the achievement of serum 25(OH)D > 50 nmol/L at 3 ± 1 months. The half-life of 25(OH)D in serum is in the range of 22–28 days. Thus, the period of this study is equivalent to 3–4 half-lives, a minimum period with a high probability of measuring a steady-state level. For safety, patients were monitored for the development of hypercalciuria (urine calcium > 7.5 mmol/day) at 3 months and hypercalcaemia (calculated calcium > 2.6 mmol/L) at 3 weeks and 3 months. Changes in serum parathyroid hormone (PTH), alkaline phosphatase (ALP) and corrected calcium were also analysed.

Biochemical assessments

Serum 25(OH)D (radioimmunoassay after extraction [DiaSorin, Stillwater, Minn, USA], coefficient of variation, 10.7%, 9.5% and 11.5% at levels of 33, 61 and 117 nmol/L, respectively), calcium, albumin, PTH, ALP and creatinine, as well as 24-hour urine calcium excretion, were measured at baseline and 3 ± 1 months. Serum calcium and albumin were also measured at 3 weeks. Calculated corrected calcium was used for analyses.

Statistical analysis

Analyses were performed on test results of all patients who attended their final assessment at 3 ± 1 months (SPSS version 16, SPSS Inc, Chicago, Ill, USA). Nonparametric tests were used because of the small number of
participants (the Wilcoxon signed-rank test or Mann–Whitney U test for continuous variables, and chi-square test for proportions). The effect of season of recruitment on baseline and changes in serum 25(OH)D was evaluated using multivariate analysis of covariance (ANCOVA). A P value of <0.05 was considered statistically significant.

RESULTS

Of 130 patients assessed for eligibility, 61 met the criteria and gave written, informed consent to participate (Box 1). Two patients were retrospectively excluded for unsuspected Paget disease of bone or active malignancy. Of the remaining 59 patients, one in each group died of acute myocardial infarction, and 23 failed to re-attend. Of the 34 completers, 26 had their final assessment at 3±1 months. The eight subjects who were tested 4–6 months from baseline had a significantly smaller increase in serum 25(OH)D than those who completed within 3±1 months (38.7±52.4 nmol/L; P=0.02), and for this reason they were excluded from the analysis. There were no statistically significant differences at baseline between completers (n=26) and non-completers (n=33), except that men were more likely to be non-completers (P=0.007). Baseline characteristics of the patients who completed the study at 3±1 months were similar between treatment groups (Box 2).

Serum 25(OH)D responses to treatment

Changes in biochemical variables are shown in Box 3. Pre- and post-treatment serum 25(OH)D levels for each individual by group are depicted in Box 4. The high-dose group (12 participants) and low-dose group (14 participants) had mean ±SD baseline 25(OH)D levels of 28±9 nmol/L and 26±9 nmol/L, respectively. A third of patients in the high-dose group and half those in the low-dose group had severe vitamin D deficiency (serum 25(OH)D <25 nmol/L). The mean increase in serum 25(OH)D was similar in both groups, reaching 55 nmol/L (95% Cl, 40–69) and 51 nmol/L (95% Cl, 44–58) in the high- and low-dose groups, respectively. Serum 25(OH)D reached a mean level of 85±21 nmol/L and 77±15 nmol/L for the high- and low-dose groups, respectively, at 3 months (P=0.4 for the difference between groups). There was no effect of season on either baseline or changes in serum 25(OH)D.

In the high- and low-dose groups, 9/10 and 13/14 of patients attained serum 25(OH)D levels >50 nmol/L, while 6/10 and 8/14 reached levels ≥75 nmol/L, respectively. Post-treatment serum 25(OH)D values were all within the physiological range (<200 nmol/L).16,17 The highest 3-month serum level of 25(OH)D (120 nmol/L) occurred within the high-dose group.

Of patients initially recruited, 20/29 in the low-dose group and 5/30 in the high-dose group (P<0.001) recalled having taken at least 80% of their vitamin D tablets. Among completers, self-reported compliance with study treatment was 12/14 (86%) in the low-dose group and 2/12 (17%) in the high-dose group.

Changes in serum calcium, urine calcium and serum creatinine

Serum calcium was normal in the 20 patients who had measurements taken 2–5 weeks after treatment initiation. At 3 months, corrected calcium increased by 0.1 mmol/L in the low-dose group (P=0.03), but no significant change occurred in the high-dose group. No patient developed hypercalcaemia. Three patients (two in the low-dose and one in the high-dose group) had 24-hour urine calcium excretions ≥7.5 mmol/day, and two patients had >10 mmol/day. No nephrolithiasis was reported.

There was a statistically significant rise in serum creatinine in the low-dose treatment

| 2 Baseline characteristics of the participants who completed the study within 3±1 months (n=26) |
|---|---|---|---|
| Reference range | Low-dose (n=14)* | High-dose (n=12)* | P value† |
| Age, years | 56.9±13.6 | 59.0±19.8 | 0.7 |
| Women, n | 13 | 11 | 1.0 |
| Participants of European ancestry, n | 13 | 9 | 0.3 |
| 25(OH)D nmol/L | 75–200 | 26±9 | 28±9 | 0.6 |
| CCa mmol/L | 2.2–2.6 | 2.3±0.1 | 2.4±0.1 | 0.4 |
| PTH pmol/L | 1.2–6.5 | 4.7±3.9 | 3.9±3.2 | 0.3 |
| ALP IU/L | 30–120 | 119±60 | 96±21 | 0.8 |
| Serum creatinine μmol/L | 50–110 | 78±23 | 77±18 | 0.8 |
| Urine calcium mmol/day | 2.5–7.5 | 2.4±2.1 | 2.9±1.5 | 0.4 |

ALP = serum alkaline phosphatase. CCa = serum corrected calcium. 25(OH)D = serum 25-hydroxyvitamin D. PTH = serum parathyroid hormone. Urine calcium = 24-hour urine calcium excretion.
* Data are mean ±SD or n (%). † P value for the difference between groups using Mann–Whitney or χ² as appropriate.

RESEARCH
group from 78±23 to 91±40 mmol/L (P = 0.004). However, all 3-month serum creatinine concentrations were within the normal range, except for one patient in the low-dose group, who developed worsening renal impairment (serum creatinine increased from 140 to 220 μmol/L).

### DISCUSSION

A regimen of high-dose oral cholecalciferol was as effective at increasing serum 25(OH)D concentrations at 3 months as a longer, low-dose regimen. In both groups, ≥ 90% of patients achieved levels of 25(OH)D >50 nmol/L, and about 60% achieved levels of ≥ 75 nmol/L, comparable with previous studies of vitamin D supplementation.15,18 Consistent with Australian data, season did not influence baseline 25(OH)D or increases in serum 25(OH)D concentrations, implying behavioural factors are more important.19

No patient developed hypercalcaemia or vitamin D toxicity. The highest serum 25(OH)D concentration reached after 3 months (120 nmol/L) was in the high-dose group, but was within the physiological range. One patient in each group had an increase in urine calcium excretion >10 mmol/day.

No patient developed nephrolithiasis, but longer follow-up and radiographic studies would be required to exclude this possibility. The association between hypercalciuria with vitamin D therapy and nephrolithiasis is unclear.15 A systematic review did not find evidence of adverse effects from higher intakes of vitamin D and noted instead that postmenopausal women who developed nephrolithiasis had higher calcium intakes.20

The low-dose group showed a significant increase in mean serum creatinine after treatment. However, this group included a patient with pre-existing mild renal impairment, hypertension and diabetes who displayed significant deterioration in renal function during the trial. As this patient did not return for follow-up, it is difficult to draw any conclusion about the contribution of vitamin D and calcium treatment to the decline in renal function.

There are limitations to our study. Firstly, neither participants nor researchers were blinded to the treatment arms, which could have resulted in cross-contamination of the treatment groups. However, this is likely to mirror clinical practice. Secondly, there was a high drop-out rate, with only 26 of the original 59 enrolled subjects (44%) attending the final assessment within the prescribed time. Although the completers and non-completers were similar, a sex difference between these groups may have influenced the results. Thirdly, compliance was assessed by questionnaire, which could be affected by recall bias. Compliance with the daily calcium supplement was not recorded, so any effect of coadministration of cholecalciferol on compliance with calcium is unknown.

It is surprising that reported compliance with the low-dose vitamin D regimen was 86%. Indeed, low adherence rates with daily cholecalciferol have been reported in previous studies.21,22 While unexpected, it is possible that the lower compliance in the high-dose group (17%) was due to patient reluctance to take what they had interpreted to be a “megadose”. Future studies would be strengthened by long-term follow-up to assess the safety and clinical relevance of the hypercalciuria, which developed in a few patients. Compliance with high-dose therapy could be optimised by patient education or by giving all ten 50 000 IU tablets at once under observation.18

This study has raised local awareness of the prevalence of hypovitaminosis D in hospitalised patients. At present, authority to prescribe tablets of cholecalciferol 50 000 IU can only be obtained in Australia through special access schemes or under section 19(5) of the Therapeutic Goods Act via hospital or community pharmacies, or via private prescriptions through compounding pharmacists at a cost of $20 for 10 tablets. The cost of the low-dose regimen is about $30 at retail pharmacies. Replacement with high-dose oral cholecalciferol may be more practical and cost-effective than longer-term, low-dose treatment. Improved access to high-dose cholecalciferol in Australia is needed.23

### Table 3

<table>
<thead>
<tr>
<th>Variable</th>
<th>Low / high dose group (n)</th>
<th>Mean change (95% CI)</th>
<th>Difference between groups in mean change (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25(OH)D nmol/L</td>
<td>Low (14)</td>
<td>51 (44–58)</td>
<td>−4 (−18–10)</td>
</tr>
<tr>
<td></td>
<td>High (10)</td>
<td>55 (40–69)</td>
<td></td>
</tr>
<tr>
<td>CCa mmol/L</td>
<td>Low (14)</td>
<td>0.06 (0.01–0.12)</td>
<td>0.07 (−0.01–0.15)</td>
</tr>
<tr>
<td></td>
<td>High (10)</td>
<td>−0.01 (−0.07–0.06)</td>
<td></td>
</tr>
<tr>
<td>PTH pmol/L</td>
<td>Low (14)</td>
<td>0.3 (−1.5–2.1)</td>
<td>−0.2 (−2.7–2.4)</td>
</tr>
<tr>
<td>ALP IU/L</td>
<td>High (8)</td>
<td>0.5 (−1.0–2.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low (11)</td>
<td>−17 (−45–11)</td>
<td>−14 (−56–28)</td>
</tr>
<tr>
<td></td>
<td>High (5)</td>
<td>−3 (−19–13)</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine μmol/L</td>
<td>Low (14)</td>
<td>14 (2–25)</td>
<td>7 (−7–21)</td>
</tr>
<tr>
<td></td>
<td>High (11)</td>
<td>6 (−1–14)</td>
<td></td>
</tr>
<tr>
<td>Urine calcium mmol/day</td>
<td>Low (10)</td>
<td>0.9 (−0.3–2.1)</td>
<td>−0.4 (−2.9–2.0)</td>
</tr>
<tr>
<td></td>
<td>High (9)</td>
<td>1.4 (−1.1–3.8)</td>
<td></td>
</tr>
</tbody>
</table>

ALP = serum alkaline phosphatase. CCa = serum corrected calcium. 25(OH)D = serum 25-hydroxyvitamin D. PTH = serum parathyroid hormone.

Evidence of adverse effects from higher intakes of vitamin D and noted instead that postmenopausal women who developed nephrolithiasis had higher calcium intakes.20

The low-dose group showed a significant increase in mean serum creatinine after treatment. However, this group included a patient with pre-existing mild renal impairment, hypertension and diabetes who displayed significant deterioration in renal function during the trial. As this patient did not return for follow-up, it is difficult to draw any conclusion about the contribution of vitamin D and calcium to the decline in renal function.

There are limitations to our study. Firstly, neither participants nor researchers were blinded to the treatment arms, which could have resulted in cross-contamination of the treatment groups. However, this is likely to mirror clinical practice. Secondly, there was a high drop-out rate, with only 26 of the original 59 enrolled subjects (44%) attending the final assessment within the prescribed time. Although the completers and non-completers were similar, a sex difference between these groups may have influenced the results. Thirdly, compliance was assessed by questionnaire, which could be affected by recall bias. Compliance with the daily calcium supplement was not recorded, so any effect of coadministration of cholecalciferol on compliance with calcium is unknown.

It is surprising that reported compliance with the low-dose vitamin D regimen was 86%. Indeed, low adherence rates with daily cholecalciferol have been reported in previous studies.21,22 While unexpected, it is possible that the lower compliance in the high-dose group (17%) was due to patient reluctance to take what they had interpreted to be a “megadose”. Future studies would be strengthened by long-term follow-up to assess the safety and clinical relevance of the hypercalciuria, which developed in a few patients. Compliance with high-dose therapy could be optimised by patient education or by giving all ten 50 000 IU tablets at once under observation.18

This study has raised local awareness of the prevalence of hypovitaminosis D in hospitalised patients. At present, authority to prescribe tablets of cholecalciferol 50 000 IU can only be obtained in Australia through special access schemes or under section 19(5) of the Therapeutic Goods Act via hospital or community pharmacies, or via private prescriptions through compounding pharmacists at a cost of $20 for 10 tablets. The cost of the low-dose regimen is about $30 at retail pharmacies. Replacement with high-dose oral cholecalciferol may be more practical and cost-effective than longer-term, low-dose treatment. Improved access to high-dose cholecalciferol in Australia is needed.23

### Figure 4

**Individual values of serum 25-hydroxyvitamin D (25(OH)D) levels pre- and post-treatment for low- and high-dose vitamin D groups**

- **Low-dose vitamin D group**
  - Pre-treatment: Serum 25(OH)D levels range from 0 to 125 mmol/L.
  - Post-treatment: Serum 25(OH)D levels range from 0 to 125 mmol/L.

- **High-dose vitamin D group**
  - Pre-treatment: Serum 25(OH)D levels range from 0 to 125 mmol/L.
  - Post-treatment: Serum 25(OH)D levels range from 0 to 125 mmol/L.
ACKNOWLEDGEMENTS

We would like to thank Key Pharmaceuticals, Australia, for providing low-dose cholecalciferol. We give special thanks also to the University of Melbourne for funding support.

COMPETING INTERESTS

None identified.

AUTHOR DETAILS

Kathryn L Hackman, MB BS, Endocrinology Registrar
Claudia Gagnon, MD, FRCP, Research Fellow
Roisin K Briscoe, BSc(Hons), Honours Student
Simon Lam, MB BS, FRACP, MRCP(UK), Rheumatologist and General Physician
Mahesan Anpalahan, MD, FRACP, MRCP(UK), Physician
Peter R Ebeling, MB BS, MD, FRACP, Professor of Medicine and Head of Endocrinology

REFERENCES


(Received 18 Sep 2009, accepted 17 Jan 2010)